Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of MT1988 in Healthy Adults
NCT06728176Phase 1Completed
- Sponsor
- Monument Therapeutics
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT1988 in schizophrenia (5 arms), sponsored by Monument Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Nov 2024; status: completed.
02
Drugs
MT1988
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06728176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728176.